The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

The World Health Organization reports that around 2.2 billion people struggle with vision problems such as near-sightedness ...

This prospective case-control study included 85 patients with lung involvement related to the COVID-19 virus and a group of ...

What you need to know about the new video connection standards that were announced earlier this year at CES 2025.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Diabetic vitreous hemorrhage is linked to neuropathologic changes in specific brain regions, as identified by voxel-based ...

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to ...